Blood clotting disorders can be inherited or acquired and lead to either excessive bleeding or too much clotting.

Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding event and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in Von ...

COPENHAGEN, Denmark and CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved ...